clofazimine has been researched along with Erythema in 9 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the expression of several cell adhesion and lymphocyte activation molecules in erythema dyschromicum perstans lesions, and to evaluate the effect of clofazimine therapy on the expression of these molecules." | 7.69 | Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. ( Baranda, L; Cortes-Franco, R; Gonzalez-Amaro, R; Moncada, B; Portales-Perez, DP; Torres-Alvarez, B, 1997) |
| "Eight patients were studied to determine the possible use of clofazimine for treating erythema dyschromicum perstans (EDP)." | 7.67 | Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity. ( Abrusci, V; Briceño, L; Convit, J; Gross, A; Mosca, W; Pérez-Alfonzo, R; Piquero-Martín, J; Tapia, F, 1989) |
| "To assess the expression of several cell adhesion and lymphocyte activation molecules in erythema dyschromicum perstans lesions, and to evaluate the effect of clofazimine therapy on the expression of these molecules." | 3.69 | Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. ( Baranda, L; Cortes-Franco, R; Gonzalez-Amaro, R; Moncada, B; Portales-Perez, DP; Torres-Alvarez, B, 1997) |
| " Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes." | 1.32 | Reactions and their management. ( Ganapati, R; Pai, VV, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rato, M | 1 |
| Monteiro, AF | 1 |
| Aranha, J | 1 |
| Tavares, E | 1 |
| Müller, A | 1 |
| Wolfsperger, F | 1 |
| Kofler, L | 1 |
| Yazdi, AS | 1 |
| Becker, L | 1 |
| Kowalewski, C | 1 |
| Martin, JM | 1 |
| Ganapati, R | 2 |
| Pai, VV | 2 |
| Farella, V | 1 |
| Lotti, T | 1 |
| Difonzo, EM | 1 |
| Panconesi, EX | 1 |
| Baranda, L | 1 |
| Torres-Alvarez, B | 1 |
| Cortes-Franco, R | 1 |
| Moncada, B | 1 |
| Portales-Perez, DP | 1 |
| Gonzalez-Amaro, R | 1 |
| Banerji, U | 1 |
| Thomas, J | 1 |
| Saha, B | 1 |
| Venkateswarlu, B | 1 |
| Venkataramana, D | 1 |
| Rao, AV | 1 |
| Prabhakar, MC | 1 |
| Reddy, BM | 1 |
| Piquero-Martín, J | 1 |
| Pérez-Alfonzo, R | 1 |
| Abrusci, V | 1 |
| Briceño, L | 1 |
| Gross, A | 1 |
| Mosca, W | 1 |
| Tapia, F | 1 |
| Convit, J | 1 |
1 trial available for clofazimine and Erythema
| Article | Year |
|---|---|
A multicenter study of recombinant interferon-alpha 2b in the treatment of multibacillary leprosy.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Erythema; Humans; Interferon Type I; Lepromin; Lepr | 1997 |
8 other studies available for clofazimine and Erythema
| Article | Year |
|---|---|
Ashy dermatosis with involvement of mucous membranes.
Topics: Anti-Inflammatory Agents; Biopsy; Clofazimine; Erythema; Female; Humans; Hyperpigmentation; Middle A | 2017 |
Multiple livid-erythematous macules and plaques with slight scaling in a young man.
Topics: Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Erythema; Humans; Lep | 2018 |
Nonpruritic erythematous plaques.
Topics: Adult; Animals; Armadillos; Biopsy; Clofazimine; Dapsone; Diagnosis, Differential; Drug Therapy, Com | 2009 |
Reactions and their management.
Topics: Arthritis; Cicatrix; Clofazimine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Ad | 2004 |
Erythema elevatum diutinum.
Topics: Biopsy; Clofazimine; Dapsone; Erythema; Female; Fluorescent Antibody Technique; Hematologic Tests; H | 1994 |
Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Cell Adhesion Molecules; Clofazimine; Erythem | 1997 |
Role of rifampin and clofazimine ointments in the treatment of leprosy.
Topics: Clofazimine; Dermatitis; Drug Combinations; Edema; Erythema; Humans; Leprosy, Tuberculoid; Ointments | 1992 |
Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity.
Topics: Adolescent; Adult; Biopsy; Child; Clofazimine; Erythema; Female; Follow-Up Studies; Humans; Immunohi | 1989 |